NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

Not Yet RecruitingPhase 1, Phase 2

Sponsor: LG Chem

Conditions: Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer

Interventions: LG00313112

This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Males and females aged 18 years or older
2. Diagnosed locally advanced unresectable or metastatic solid tumor with a TP53 Y220C mutation.
3. Documented disease progression during or after the most recent line of therapy. In addition, must be refractory to or intolerant of standard of care therapy or have no standard therapy.
4. Measurable disease per RECIST v1.1.
5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
6. Adequate organ function.

Exclusion Criteria:

1. Investigational therapy or anti-cancer therapy within 21 days or 5 half-lives prior to the first dose of study drug.
2. Radiotherapy within 14 days prior to the first dose of study drug.
3. Known brain metastases (Exception: Brain metastases are permitted if the participant is neurologically stable), leptomeningeal disease or carcinomatous meningitis.
4. Uncontrolled pleural effusion, pericardial effusion, or ascites.
5. History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease
6. Serious infections requiring intravenous antibiotics within 14 days of first dose of study drug.
7. Active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection
8. Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease
9. History of prior organ transplant
10. Currently receiving strong Cytochrome P4503A (CYP3A4) inhibitors or inducers